FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028282038> ?p ?o ?g. }

• W2028282038 endingPage "S137" @default.
• W2028282038 startingPage "S137" @default.
• W2028282038 abstract "s of the 4th Congress of ECCO the European Crohn’s and Colitis Organisation S103 P233 Prevalence of antibodies recognizing cyclic citrullinated peptides (anti-CCP) in patients with ulcerative colitis R. Tirri1, A. de Leone2 *, S. Giaquinto2, R. Vitiello1, A. Cirillo2, G. Valentini1, G. Riegler2. 1Unit of Rheumathology, Department of Internal Medicine F. Magrassi A. Lanzara, Second University of Naples, Naples, Italy, 2Unit of Gastroenterology, Department of Internal Medicine F. Magrassi A. Lanzara, Second University of Naples, Naples, Italy Aim: Ulcerative Colitis (UC) and Crohn’s disease (CD) are the most common forms of Inflammatory Bowel Diseases (IBD) while Aspecific Chronic Colitis (ACC) and Indeterminate Colitis (IC) are less frequent. IBD are frequently complicated by joint involvement (peripheral and axial arthritis). Antibodies recognizing cyclic citrullinated peptides (anti-CCP) are directed to proteins that contain the unusual amino acid citrulline [1]. The anti-CCP ELISA test has an excellent specificity for the diagnosis of Rheumatoid Arthritis (RA), especially in patients with early disease, and it is considered a disease activity predictor [2]. Anti-CCP positivity is detected also in Psoriatic Arthritis (PA) but associated with symmetrical polyarthritis pattern [3]. Correlation between IBD, with or without arthritic manifestations, and anti-CCP positivity was not founded [4]. The aim of our study was to evaluate the role of anti-CCP in IBD patients with arthritic manifestations (Enteropathic Arthritis, EA), with arthritic manifestations and Psoriasis (EA + Ps) and in IBD patients without extraintestinal manifestations. Materials and Methods: A total of 54 consecutive adult patients with IBD (24: 19 UC, 3 CD and 2 ACC), with EA (16: 10 UC, 5 CD and 1 IC) and with EA + Ps (14: 6 UC, 7 CD and 1 ACC) were evaluated. Anti-CCP antibodies were detected on patients serum samples by a second generation ELISA test (VCP-IgG Kit; ASTRA Srl Milano) and as positive results were defined values >25U/mL. Results: Anti-CCP positivity was detected in 8 of 54 patients (15%): 4 IBD (3 UC and 1 ACC), 2 EA (2 UC) and 2 EA + Ps (1 UC and 1 ACC). No significant difference (p > 0.05) of the prevalence of antiCCP was found among patients with EA, patients with EA + PS and IBD patients without arthritic manifestations and also among the three groups with different articular involvement. Instead, UC patients had significantly higher prevalence (p 0.05). The overall allele frequency of mutations was higher in CD patients (39.29%) than in controls (27.27%) and this was not statistically significant (p = 0.1595). Polymorphisms Genotype Allele P*" @default.
• W2028282038 created "2016-06-24" @default.
• W2028282038 creator A5025852856 @default.
• W2028282038 creator A5029752315 @default.
• W2028282038 creator A5036215659 @default.
• W2028282038 creator A5043366841 @default.
• W2028282038 creator A5051535034 @default.
• W2028282038 creator A5091236920 @default.
• W2028282038 creator A5091824050 @default.
• W2028282038 date "2009-03-01" @default.
• W2028282038 modified "2023-09-25" @default.
• W2028282038 title "PREVALENCE OF ANTIBODIES RECOGNIZING CYCLIC CITRULLINATED PEPTIDES (ANTI-CCP) IN PATIENTS WITH ULCERATIVE COLITIS" @default.
• W2028282038 doi "https://doi.org/10.1016/s1590-8658(09)60360-1" @default.
• W2028282038 hasPublicationYear "2009" @default.
• W2028282038 type Work @default.
• W2028282038 sameAs 2028282038 @default.
• W2028282038 citedByCount "0" @default.
• W2028282038 crossrefType "journal-article" @default.
• W2028282038 hasAuthorship W2028282038A5025852856 @default.
• W2028282038 hasAuthorship W2028282038A5029752315 @default.
• W2028282038 hasAuthorship W2028282038A5036215659 @default.
• W2028282038 hasAuthorship W2028282038A5043366841 @default.
• W2028282038 hasAuthorship W2028282038A5051535034 @default.
• W2028282038 hasAuthorship W2028282038A5091236920 @default.
• W2028282038 hasAuthorship W2028282038A5091824050 @default.
• W2028282038 hasConcept C126322002 @default.
• W2028282038 hasConcept C159654299 @default.
• W2028282038 hasConcept C16005928 @default.
• W2028282038 hasConcept C203014093 @default.
• W2028282038 hasConcept C2779134260 @default.
• W2028282038 hasConcept C2780479503 @default.
• W2028282038 hasConcept C71924100 @default.
• W2028282038 hasConcept C90924648 @default.
• W2028282038 hasConceptScore W2028282038C126322002 @default.
• W2028282038 hasConceptScore W2028282038C159654299 @default.
• W2028282038 hasConceptScore W2028282038C16005928 @default.
• W2028282038 hasConceptScore W2028282038C203014093 @default.
• W2028282038 hasConceptScore W2028282038C2779134260 @default.
• W2028282038 hasConceptScore W2028282038C2780479503 @default.
• W2028282038 hasConceptScore W2028282038C71924100 @default.
• W2028282038 hasConceptScore W2028282038C90924648 @default.
• W2028282038 hasLocation W20282820381 @default.
• W2028282038 hasOpenAccess W2028282038 @default.
• W2028282038 hasPrimaryLocation W20282820381 @default.
• W2028282038 hasRelatedWork W181348724 @default.
• W2028282038 hasRelatedWork W2025048290 @default.
• W2028282038 hasRelatedWork W2086156447 @default.
• W2028282038 hasRelatedWork W2375240245 @default.
• W2028282038 hasRelatedWork W2464962541 @default.
• W2028282038 hasRelatedWork W2475104063 @default.
• W2028282038 hasRelatedWork W2765379856 @default.
• W2028282038 hasRelatedWork W2896381073 @default.
• W2028282038 hasRelatedWork W4210249856 @default.
• W2028282038 hasRelatedWork W4322722440 @default.
• W2028282038 hasVolume "41" @default.
• W2028282038 isParatext "false" @default.
• W2028282038 isRetracted "false" @default.
• W2028282038 magId "2028282038" @default.
• W2028282038 workType "article" @default.